



NATIONAL BREAST CANCER COALITION

2023 BREAST CANCER

FACTS & FIGURES


The National Breast Cancer Coalition (NBCC) is a grassroots organization dedicated to ending breast cancer through action and advocacy.

INCIDENCE

Breast cancer is the most diagnosed cancer among women in the U.S.* In 2023, there will be an estimated **297,790** new cases of invasive breast cancer in women, **2,800** new cases in men, and an additional **55,720** cases of ductal carcinoma in situ (DCIS)** in women.***1

Lifetime Risk

For women in the U.S., the lifetime risk of being diagnosed with invasive breast cancer has increased since 1975.^{2,3}



Incidence By Age

Older women are more likely to get invasive breast cancer than younger women. From 2015-2019, the median age of a breast cancer diagnosis was 62 years.²

*Excluding basal cell and squamous cell skin cancers, which are not required to be reported to cancer registries, and carcinomas in situ.

**Annual incidence counts of lobular carcinoma in situ are no longer measured following its removal from the 2017 edition of the AJCC breast cancer staging program.

***These statistics do not account for the effect of the COVID-19 pandemic.

MORTALITY



In 2020, **685,000** women died from breast cancer globally.⁴

Breast cancer is **the 2nd leading cause of cancer deaths for women**

in the United States, after lung cancer.

In 2023, it is estimated that **43,170 women** and **530 men** will die of breast cancer.*¹

Progress in reducing breast cancer mortality has slowed in recent years, from 2% to 3% annually during the 1990s and 2000s to 1% annually from 2011 to 2020.²

While the breast cancer mortality rate has declined, the number of women and men who die each year is rising and will continue to rise as the aging population grows.

Mortality By Age

From 2016-2020, the median age at death from breast cancer was **70 years** of age.⁵



Every 13 minutes, a woman dies from breast cancer.

*These statistics are based on 2020 mortality data and account for the first year only of the COVID-19 pandemic.

RACIAL DISPARITIES



Despite a similar incidence, mortality from breast cancer among Black women is **40% higher** compared with White women.^{1,2}

INCIDENCE & MORTALITY RATES

Incidence Rate Per 100,000 by Race/Ethnicity (2015-2020)

White	133.7
Black	127.8
American Indian / Alaska Native	111.3
Asian American / Pacific Islander	101.3
Hispanic/Latino	99.2

Mortality Rate Per 100,000 by Race/Ethnicity (2015-2020)

White	19.7
Black	27.6
American Indian / Alaska Native	20.5
Asian American / Pacific Islander	11.7
Hispanic/Latino	13.7

RECURRENCE

The risk of local and distant (metastatic) recurrence varies greatly based on many factors. Estimates of long-term cumulative risk range from about 5% to 60%, with most falling between **10%-30%**.⁶⁻⁹ Furthermore, recurrence risk remains elevated more than 3 decades from the primary diagnosis.⁹

PREVALENCE

As of January 2022, there were an estimated **>4 million** women living with a history of invasive breast cancer in the U.S.¹⁰

It is estimated that in 2018, **140,230** women in the U.S. were living with metastatic breast cancer. By 2025, this number is expected to increase to **169,347**.¹¹

RISK FACTORS

Only 5-10% of breast cancers are hereditary. The strongest risks for breast cancer are age and being assigned female at birth.

Other non-modifiable risk factors include:¹²⁻¹⁴

- ◆ Genetic mutations, such as in *BRCA1* and *BRCA2*
- ◆ Starting menstrual periods before age 12 and menopause after age 55
- ◆ Having dense breasts
- ◆ Personal history of breast cancer or benign breast diseases
- ◆ Family history of breast cancer
- ◆ Previous radiation therapy in chest or breasts
- ◆ Exposure to the drug diethylstilbestrol (DES)
- ◆ Naturally high levels of estrogen or testosterone


Risk factors that are potentially modifiable include:

- ◆ Lack of physical activity
- ◆ Being overweight or having obesity (post-menopause)
- ◆ Taking hormonal medications, such as menopausal hormone therapy or hormonal contraceptives
- ◆ Reproductive history, including being over 30 years of age at first full-term pregnancy, not breastfeeding, and never having a full-term pregnancy
- ◆ Alcohol consumption

DCIS & SCREENING

The diagnosis of ductal carcinoma in situ (DCIS) was rare before 1980, but the widespread adoption of screening mammography led to a massive increase in DCIS diagnosis. From 1980-2000, women aged 20-49 experienced a **400% increase** in DCIS diagnoses, and women over the age of 50 experienced over a **900% increase** in DCIS diagnoses.² However, screening has not decreased the rate of lethal disease (i.e., distant stage) at diagnosis.¹⁵

Overdiagnosis of breast cancer (i.e., cancer that would never have become a problem) by screening mammography is difficult to determine, with the most credible estimates ranging from **11%-22%**.^{16,17} False positive and false negative mammography results are also



possible. Over a 10-year period, **more than half** of women getting an annual mammogram will receive a false-positive result.^{18,19}

TREATMENT

The current methods of treatment in use in the U.S.

**Surgery
(Mastectomy
& Lumpectomy)**



Chemotherapy



Radiation



Hormonal



**Targeted
Therapy**



Immunotherapy

LANGUAGE

NBCC acknowledges that breast cancer impacts people of all gender identities.

REFERENCES

1. Siegel, R. L. *et al.* Cancer statistics, 2023. *CA. Cancer J. Clin.* **73**, 17–48 (2023).
2. American Cancer Society. Breast Cancer Facts & Figures 2022-2024. (2022).
3. Feuer, E. J. *et al.* The Lifetime Risk of Developing Breast Cancer. *JNCI J. Natl. Cancer Inst.* **85**, 892–897 (1993).
4. World Health Organization. Breast cancer. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer> (2021).
5. National Cancer Institute. Cancer of the Breast (Female) - Cancer Stat Facts. SEER <https://seer.cancer.gov/statfacts/html/breast.html> (2022).
6. Saphner, T. *et al.* Annual hazard rates of recurrence for breast cancer after primary therapy. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **14**, 2738–2746 (1996).
7. Colleoni, M. *et al.* Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. *J. Clin. Oncol.* **34**, 927–935 (2016).
8. Pan, H. *et al.* 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *N. Engl. J. Med.* **377**, 1836–1846 (2017).
9. Pedersen, R. N. *et al.* The Incidence of Breast Cancer Recurrence 10–32 Years After Primary Diagnosis. *JNCI J. Natl. Cancer Inst.* **114**, 391–399 (2022).
10. Miller, K. D. *et al.* Cancer treatment and survivorship statistics, 2022. *CA. Cancer J. Clin.* **72**, 409–436 (2022).
11. Gallicchio, L. *et al.* Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. *JNCI J. Natl. Cancer Inst.* **114**, 1476–1483 (2022).
12. American Cancer Society. *Cancer Facts & Figures 2023*. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf> (2023).
13. Centers for Disease Control and Prevention. Hereditary Breast Cancer and BRCA Genes | Bring Your Brave. https://www.cdc.gov/cancer/breast/young_women/bringyourbrave/hereditary_breast_cancer/index.htm (2022).
14. Centers for Disease Control and Prevention. What Are the Risk Factors for Breast Cancer? https://www.cdc.gov/cancer/breast/basic_info/risk_factors.htm (2022).
15. National Cancer Institute. Breast Recent Trends in SEER Age-Adjusted Incidence Rates, 2000–2019. https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&data_type=1&graph_type=2&compareBy=stage&chk_stage_101=101&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&hdn_rate_type=1&sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#graphArea.
16. Ryser, M. D. *et al.* Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. *Ann. Intern. Med.* **175**, 471–478 (2022).
17. Nelson, H. *et al.* Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventative Services Task Force Recommendation. <https://www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-harms-of-screening-for-breast-cancer/breast-cancer-screening> (2016).
18. American Cancer Society. Limitations of Mammograms. <https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html> (2023).
19. Hubbard, R. A. *et al.* Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography. *Ann. Intern. Med.* **155**, 481–492 (2011).